glp-1 receptor agonists dizziness side effect Adverse effects of agonists: Clinical Implications, regulatory perspectives, and future directions The expanding role of GLP-1

This increased risk was confined to women using GLP-1 receptor agonists for diabetes treatment (liraglutide aOR 1.70, 95% CI 1.172.48

Andrej Jane has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Abbott, Novo Nordisk, Novartis and Swixx

doi: 10.1152/ajpendo.1996.271.3.E458

Actual results may differ significantly

The detail is contained within two recent publications in prestigious, peer-reviewed medical journals: Doctors at the University of North Carolina in America conducted a small clinical trial of GLP-1 in pouchees who had a high frequency of bowel movements but with a normal pouch (i.e., no inflammation)

Whats emerging here is a new paradigm where: neuronal energy metabolism becomes a therapeutic target